Capecitabine Tablets Usp 150mg (ndc 68001 487 06) Rev 0921 Intas Pharmez Site
 Rev 0921 Intas Pharmez Site.jpg)
Capecitabine Tablet, Film Coated
Product Images NDC 68001-487
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 68001-487). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bluepoint Laboratories, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Capecitabine Tablets 150mg 60's Bottle Label (Capecitabine 150 Label)
Each tablet contains 150mg of Capecitabine, a cytotoxic agent. The tablets should be swallowed whole with water and should not be crushed or cut. It is recommended to store the tablets in tight containers and in controlled room temperature between 15°C - 30°C. For proper dosage and prescribing information, please refer to the accompanying insert. These tablets are manufactured by Intas Pharmaceuticals Limited, Ahmedabad-382 210, INDIA, for BluePoint Laboratories. Total quantity in one package is 60 Tablets.*
Capecitabine Tablets 500mg 120's Bottle Label (Capecitabine 500 Label)
Figure 1 (Capecitabine Fig1)
Figure 2 (Capecitabine Fig2)
The text is not readable.*
Figure 3 (Capecitabine Fig3)
The provided text represents a chart displaying estimated probabilities for a certain treatment (namely, 5-FU + Leucovorin or Capecitabine at 1250mg/sqm e daily) administered intermittently over a period of time. The x-axis represents time in days, with values ranging from 0 to 1500. The y-axis represents estimated probability percentages, with values ranging from 0.0 to 10.0. The chart indicates that the treatment's effectiveness is expected to improve over time, with higher probabilities associated with longer periods of treatment.*
Figure 4 (Capecitabine Fig4)
Figure 5 (Capecitabine Fig5)
Chemical Structure (Capecitabine Met Path)
Chemical Structure (Capecitabine Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
